Technical Data
C0030-03B3
CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A, p90)
Description:
Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.

Applications:
Suitable for use in ELISA, Western Blot, Immunofluorescence and Immunocytochemistry. Other applications not tested.

Recommended Dilutions:
Western Blot: 0.5-2ug/ml. A band is seen at ~90kD
Optimal dilutions to be determined by the researcher.

Recommended Control:
H1838: HeLa Nuclear Extract

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2b,k8B68Affinity Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
A C-terminal portion of the human p90 protein. Cellular Localization: Cytoplasmic
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in Tris-glycine, 150mM sodium chloride, 0.05% sodium azide.
Specificity:
Recognizes a 300aa portion of human CIP2A (p90 autoantigen).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Junttila, M.R., et al. CIP2A Inhibits PP2A in Human Malignancies. Cell. 130: 51-62 (2007) 2. Shi, F.D., et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor associated antigens. Prostate. 63: 252-258. (2005) 3. Li W. Clin Cancer Res. Jun 15; 14(12):3722-8 (2008)